Clinical Pharmacy Reviewer for PLE Philippines 2026

By LisensyaPrep Team | Last Updated: May 2026 | 11-minute read

Clinical pharmacy is where pharmaceutical science meets direct patient care. It is the discipline that ensures patients receive the right drug, at the right dose, via the right route, for the right duration. The PLE tests clinical pharmacy through scenario-based questions that require integrating drug knowledge with patient-specific factors.

Pharmacokinetics: What the Body Does to the Drug

Pharmacokinetics describes the movement of drugs through the body. The four processes are absorption, distribution, metabolism, and excretion, commonly remembered as ADME.

Absorption

Absorption is the movement of a drug from its site of administration into the systemic circulation.

Bioavailability (F): The fraction of an administered dose that reaches systemic circulation unchanged. IV administration has 100% bioavailability. Oral drugs undergo first-pass metabolism in the liver before reaching systemic circulation, reducing bioavailability.

First-pass effect: Drugs absorbed from the GI tract pass through the portal vein to the liver before entering systemic circulation. Extensive first-pass metabolism significantly reduces bioavailability of some drugs. Examples of high first-pass drugs: morphine, lidocaine, propranolol, nitroglycerin (sublingual route bypasses first-pass).

Factors affecting oral absorption: Gastric pH, gastric motility, food-drug interactions, drug solubility, formulation factors.

Distribution

Distribution describes how a drug spreads from the bloodstream to tissues.

Volume of distribution (Vd): A theoretical volume that would be required to contain the total amount of drug at the same concentration found in the plasma. High Vd means drug distributes extensively into tissues. Low Vd means drug stays mostly in plasma.

Protein binding: Most drugs bind to plasma proteins, primarily albumin (for acidic drugs) and alpha-1-acid glycoprotein (for basic drugs). Only the free (unbound) fraction is pharmacologically active.

Blood-brain barrier (BBB): Only lipophilic, non-ionized, protein-unbound drugs cross the BBB. This limits CNS effects of many drugs and must be considered for CNS infections requiring antibiotics.

Metabolism

Most drug metabolism occurs in the liver via cytochrome P450 (CYP450) enzymes.

Excretion

The kidneys are the primary organ of drug excretion. Renal excretion involves glomerular filtration, tubular secretion, and tubular reabsorption.

Creatinine clearance (CrCl): Used to estimate glomerular filtration rate (GFR) and adjust doses of renally eliminated drugs. The Cockcroft-Gault equation is used clinically.

CrCl (mL/min) = [(140 − age) × weight in kg] ÷ (72 × serum creatinine)

For females, multiply the result by 0.85.

Drugs requiring dose adjustment in renal impairment: aminoglycosides, vancomycin, digoxin, metformin, most antibiotics.

Pharmacodynamics: What the Drug Does to the Body

Drug-Receptor Interactions

Agonist: Binds to a receptor and activates it, producing a pharmacological effect. Example: morphine is an agonist at opioid receptors.

Antagonist: Binds to a receptor but does not activate it. Blocks the action of agonists. Example: naloxone is an opioid receptor antagonist used to reverse opioid overdose.

Partial agonist: Binds and activates the receptor but produces a submaximal effect even at full receptor occupancy. Example: buprenorphine at opioid receptors.

Therapeutic Index

Therapeutic index (TI) = LD50 ÷ ED50

A narrow therapeutic index (NTI) means there is a small difference between the therapeutic dose and the toxic dose. NTI drugs require close monitoring.

NTI drugs to know for the PLE: Digoxin, warfarin, lithium, phenytoin, theophylline, aminoglycosides, vancomycin, cyclosporine.

Clinical Drug Management by Disease

Hypertension

First-line agents: ACE inhibitors (enalapril, lisinopril), ARBs (losartan, valsartan), calcium channel blockers (amlodipine), thiazide diuretics (hydrochlorothiazide).

ACE inhibitor key adverse effect: Dry cough (bradykinin accumulation). Switch to ARB if intolerable.

Contraindications: ACE inhibitors and ARBs are contraindicated in pregnancy (teratogenic). Beta-blockers are contraindicated in asthma.

Diabetes Mellitus

Type 1 DM: Requires insulin. Absolute insulin deficiency due to autoimmune destruction of beta cells.

Type 2 DM: First-line treatment is metformin (unless contraindicated by renal impairment, CrCl less than 30). Mechanism: decreases hepatic glucose production.

Sulfonylureas (glibenclamide, glipizide): Stimulate insulin secretion. Risk of hypoglycemia.

SGLT-2 inhibitors (empagliflozin, dapagliflozin): Inhibit glucose reabsorption in the kidney. Additional benefit: cardiovascular and renal protection.

GLP-1 agonists (semaglutide, liraglutide): Stimulate insulin secretion, inhibit glucagon, slow gastric emptying, reduce appetite. Weight loss benefit.

Antimicrobial Therapy

Beta-lactams (penicillins, cephalosporins, carbapenems): Inhibit cell wall synthesis by binding to penicillin-binding proteins (PBPs). Bactericidal.

Mechanism of resistance: Beta-lactamase production. Overcome with beta-lactamase inhibitors (clavulanate, sulbactam, tazobactam).

Aminoglycosides (gentamicin, amikacin): Inhibit protein synthesis at 30S ribosome. Bactericidal. Narrow therapeutic index. Monitor peak and trough levels. Nephrotoxic and ototoxic.

Fluoroquinolones (ciprofloxacin, levofloxacin): Inhibit DNA gyrase and topoisomerase IV. Bactericidal. Avoid in children (cartilage damage) and pregnancy.

Therapeutic Drug Monitoring (TDM)

TDM involves measuring drug concentrations in the blood to ensure therapeutic levels are achieved without toxicity.

Drug Interactions of Clinical Significance

Warfarin interactions: Warfarin has the most clinically significant drug interactions of any common medication. CYP450 inducers (rifampicin, carbamazepine) decrease warfarin levels, reducing anticoagulant effect. CYP450 inhibitors (fluconazole, amiodarone) increase warfarin levels, increasing bleeding risk.

Metformin and contrast media: Metformin should be held 48 hours before and after IV iodinated contrast to prevent lactic acidosis in patients with contrast-induced nephropathy.

Statins and CYP3A4 inhibitors: Simvastatin and lovastatin are metabolized by CYP3A4. Concurrent use with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) dramatically increases statin levels and risk of myopathy and rhabdomyolysis.

MAO inhibitors and sympathomimetics: Combination causes hypertensive crisis. MAOIs also interact with opioids (especially meperidine) causing serotonin syndrome.

Practice What You Just Learned

Clinical pharmacy questions in the PLE present patient scenarios requiring you to select the correct drug, identify an interaction, or recognize a toxicity pattern. Practice those scenarios now at LisensyaPrep. No account needed.

Practice Clinical Pharmacy Questions at LisensyaPrep